- Global Pharma News & Resources

Acute Migraine Treatment Market is anticipated to surpass US$ 8.6 Billion by 2032

From 2022 to 2032, the global Acute Migraine Treatment market revenue is anticipated to be worth US$ 8.6 billion, with a CAGR of 4.9%. In 2022, Acute Migraine Treatment market was held at around US$ 2.4 billion. Because of the fast adoption of unhealthy lifestyles, the rising prevalence of migraine is projected to boost demand for Acute Migraine Treatment alternatives in the near future.

Acute Migraine Treatment: Market Insights
Acute Migraine is episodic, unpredictable headache disorder which is characterized by recurrent attacks. Migraine is the third most prevalent disease worldwide. Acute migraine causes severe throbbing pain and pulsing sensation usually on one side of head. People with acuter migraine have headaches for 14 days a month. People with Acute migraine have fewer headache a month than the people with chronic one. Despite the vast number of migraine cases, only a small percentage of people go for the checkup.

To remain ‘ahead’ of your competitors, request for a sample@

However, growing awareness and emergence of new therapies for the treatment of acuter migraine will significantly increase the market for Acute Migraine Treatment in the near future. More than hundreds of clinical trials under going for the Acute Migraine Treatment with more than twenty trial are in the phase 4 which will create huge opportunity for the Acute Migraine Treatment market to rapidly grow in the forecast period. Currently, there are limited number of pharmacological options available for the Acute Migraine Treatment such as triptans, NSAIDs etc. Furthermore, development of new drug provide huge potential for the Acute Migraine Treatment market to fuel in the forecast period.

Acute Migraine Treatment: Market Dynamics
Rising number of population, growing prevalence of migraine is expected to drive the market of Acute Migraine Treatment is the forecast period. Increasing number of female population as the disease is more prevalent in the females further accelerate the growth of Acute Migraine Treatment market. Growing healthcare expenditure, rising adoption of unhealthy lifestyle, growing awareness regarding the acute migraine and its treatment further spur the market of Acute Migraine Treatment globally.

However, stringent regulation for the drug approval, high cost of treatment, adverse side effect, lack of proper diagnosis and growing preference of alternative therapies are some of the factors which hinder the growth of Acute Migraine Treatment market.

Last few days to get reports at discounted prices, offer expires soon!

Request Discount@

Acute Migraine Treatment: Overview
Emergence of new drug and therapies for the Acute Migraine Treatment is expected to account for the significant growth of the Acute Migraine Treatment in the forecast period. Development of new drugs such as CGRP antagonists provide huge potential for the Acute Migraine Treatment market to grow. Development of new drugs by the key pharmaceutical players such as Amgen, Novartis, Eli Lily and Company and increasing research and development funding will create huge opportunity for the market to grow in the near future. For instance, in 2017, Eli Lilly and Company’s drug for Acute Migraine Treatment succeeded in a key late-stage study, setting the stage for regulatory approval in US

Acute Migraine Treatment: Region-wise Outlook

The North America is expected to contribute to a major share in the global Acute Migraine Treatment, due to growing prevalence of acute migraine along with the increasing funding for the development of new drug with the presence of major pharmaceutical industries. According to Migraine Research Foundation, 39 million of US population suffer from migraine and 1 billion populations worldwide. 18% of women, 6% of men, and 10% of children suffers from migraines. In 2015, the medical cost of treating migraine was more than $5.4 billion, although migraine patients spent over $41 billion on treating entire range of migraine.

Europe accounts for the second largest market share and register significant growth in the global Acute Migraine Treatment market, due to increasing demand of effective treatment for the acute migraine and adoption of new therapies along with the favorable reimbursement scenarios. Asia Pacific market is primarily driven by the factors such as increasing expenditure of healthcare systems, improvement in the healthcare infrastructure and growing awareness of disease. China is expected to register significant growth in the Acute Migraine Treatment market, due to growing population, low cost of drug and treatment, availability of drugs for the Acute Migraine Treatment. Latin America and Middle East & Africa are projected to show sluggish growth in Acute Migraine Treatment market, due to lack of developed healthcare facilities.

Acute Migraine Treatment: Key Players
Some of the key players present in the global Acute Migraine Treatment market are Amgen, Pfizer Inc., Hoffmann-La Roche Ltd, Eli Lily and Company, Novartis AG, Johnson and Johnson, Merck & Co., AstraZeneca and Teva Pharmaceutical among others.

We Offer tailor-made Solutions to fit Your Requirements, Request Customization@

Key Segments Profiled in the Acute Migraine Treatment Industry Survey

By Drug Type:

  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • Triptans
  • Dihydroergotamine
  • Nonspecific Migraine Medications
  • Analgesics

By Distribution Channel:

  • Hospitals Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • E-Commerce

About Future Market Insights, Inc.

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.


Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries:
Browse All Reports:

Editor Details

Last Updated: 26-Apr-2023